Revelation Biosciences Files 8-K
Ticker: REVBW · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1810560
| Field | Detail |
|---|---|
| Company | Revelation Biosciences, Inc. (REVBW) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $193,200.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, regulatory-filing
Related Tickers: REVB
TL;DR
REVB files 8-K with financial updates, no major news.
AI Summary
Revelation Biosciences, Inc. filed an 8-K on February 11, 2025, reporting on events as of February 10, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text. The company, formerly known as Petra Acquisition Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This 8-K filing indicates that Revelation Biosciences, Inc. is providing updated financial statements and exhibits to the SEC, which is a standard regulatory requirement.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- REVELATION BIOSCIENCES, INC. (company) — Registrant
- February 10, 2025 (date) — Earliest event reported
- February 11, 2025 (date) — Date of report
- Petra Acquisition Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- 4660 La Jolla Village Drive Suite 100 (address) — Business address
- San Diego, California (location) — City and State
FAQ
What is the primary purpose of this 8-K filing for Revelation Biosciences, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and to provide 'Financial Statements and Exhibits' as of February 10, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 10, 2025.
What was Revelation Biosciences, Inc. formerly known as?
Revelation Biosciences, Inc. was formerly known as Petra Acquisition Inc.
In which state is Revelation Biosciences, Inc. incorporated?
Revelation Biosciences, Inc. is incorporated in Delaware.
What is the business address of Revelation Biosciences, Inc.?
The business address of Revelation Biosciences, Inc. is 4660 La Jolla Village Drive, Suite 100, San Diego, California, 92122.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-02-11 16:05:25
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
- $193,200.00 — of common stock at an exercise price of $193,200.00 per share REVBW The Nasdaq Stock Ma
Filing Documents
- revb-20250210.htm (8-K) — 49KB
- revb-ex99_1.htm (EX-99.1) — 15KB
- revb-ex99_1s1.jpg (GRAPHIC) — 162KB
- revb-ex99_1s2.jpg (GRAPHIC) — 704KB
- revb-ex99_1s3.jpg (GRAPHIC) — 244KB
- revb-ex99_1s4.jpg (GRAPHIC) — 188KB
- revb-ex99_1s5.jpg (GRAPHIC) — 215KB
- revb-ex99_1s6.jpg (GRAPHIC) — 135KB
- revb-ex99_1s7.jpg (GRAPHIC) — 264KB
- revb-ex99_1s8.jpg (GRAPHIC) — 298KB
- revb-ex99_1s9.jpg (GRAPHIC) — 118KB
- revb-ex99_1s10.jpg (GRAPHIC) — 299KB
- revb-ex99_1s11.jpg (GRAPHIC) — 112KB
- revb-ex99_1s12.jpg (GRAPHIC) — 189KB
- revb-ex99_1s13.jpg (GRAPHIC) — 219KB
- revb-ex99_1s14.jpg (GRAPHIC) — 131KB
- revb-ex99_1s15.jpg (GRAPHIC) — 118KB
- revb-ex99_1s16.jpg (GRAPHIC) — 342KB
- revb-ex99_1s17.jpg (GRAPHIC) — 314KB
- revb-ex99_1s18.jpg (GRAPHIC) — 198KB
- revb-ex99_1s19.jpg (GRAPHIC) — 284KB
- revb-ex99_1s20.jpg (GRAPHIC) — 311KB
- revb-ex99_1s21.jpg (GRAPHIC) — 356KB
- revb-ex99_1s22.jpg (GRAPHIC) — 399KB
- revb-ex99_1s23.jpg (GRAPHIC) — 253KB
- 0000950170-25-017882.txt ( ) — 8275KB
- revb-20250210.xsd (EX-101.SCH) — 47KB
- revb-20250210_htm.xml (XML) — 7KB
01 Other Events
Item 8.01 Other Events. On February 10, 2025, Revelation Biosciences, Inc. (the "Company") made an updated corporate presentation available to the public, the corporate presentation can be found on the Company's website. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in Item 8.01 and in Exhibit 99.1 will not be treated as "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation dated February 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: February 11, 2025 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)